Collegium Pharmaceutical (COLL) Net Cash Flow (2014 - 2026)

Collegium Pharmaceutical has reported Net Cash Flow for 13 years, with the latest figure at -$139.2 million in Q2 2026.

• On a quarterly basis, Net Cash Flow fell 757.93% year-over-year to -$139.2 million in Q2 2026; TTM through Jun 2026 was $12.1 million, a 133.98% increase from a year earlier, with the FY2025 full-year figure at $155.5 million, up 208.48% from the prior year.
• Net Cash Flow was -$139.2 million for Q2 2026 at Collegium Pharmaceutical, down from $37.4 million in the prior quarter.
• The five-year high for Net Cash Flow was $95.8 million in Q1 2023, with the low at -$139.2 million in Q2 2026.
• Average Net Cash Flow over 5 years is -$2.1 million, with a median of $14.4 million recorded in 2022.
• The largest YoY upside for Net Cash Flow was 680.51% in 2022 against a maximum downside of 1019.16% in 2022.
• Over 5 years, Net Cash Flow stood at $39.6 million in 2022, then sank by 149.5% to -$19.6 million in 2023, then soared by 261.37% to $31.6 million in 2024, then jumped by 156.79% to $81.2 million in 2025, then tumbled by 271.49% to -$139.2 million in 2026.
• The last three Net Cash Flow figures came in at -$139.2 million (Q2 2026), $37.4 million (Q1 2026), and $81.2 million (Q4 2025), per Business Quant data.